Objective: To establish whether there is a relationship between hyperprolactinemia and primary thyroid disorders, focusing on patients with autoimmune features. Materials and methods: The medical records of 100 patients with hyperprolactinemia (HPRL) were retrospectively examined. Records of thyroid ultrasonography (USG), basal serum levels of thyroid stimulating hormone, circulating free thyroxine, free triiodothyronine, antithyroglobulin (anti-Tg), and antithyroperoxidase (anti-TPO) antibodies were analyzed. In 100 control subjects, matched by age and gender with HPRL patients, thyroid USG, thyroid function tests (TFTs), and autoantibody panel were obtained. Results:
INTRODUCTION
Prolactin (PRL) is a polypeptide hormone discovered more than 70 years ago to be a pituitary factor that stimulates mammary gland development and lactation (1, 2) . It is not only produced by lactotrophic cells of the anterior pituitary gland, but also by various extrapituitary sites as neurons, prostate, decidua, mammary epithelium, skin, and immune cells (3) . Over the past decade, PRL has been linked to an extended family of proteins, referred to as hematopoietic cytokines (3) . The classification of PRL as a cytokine has been based on several molecular and functional evidences. First, its receptor is a member of the cytokine receptor superfamily. Second, PRL is predicted to adopt the upup-down-down four α-helix bundle fold characteristic of hematopoietic cytokines (4, 5) . Third, similar to well-recognized cytokines, PRL was shown to act on cells of the immune system (6, 7) .
For the time being, the only characterized disorder related to PRL is hyperprolactinemia (HPRL), which is responsible for almost 25% of menstrual cycle disorders in women. It can also be argued that PRL should be included in the list of factors favoring the proliferation of certain tumors, e.g. breast and prostate cancer (8, 9) . Besides these diseases linked to abnormal levels of circulating PRL, a role in the pathogenesis of autoimmune diseases has been suggested. Hyperprolactinemia has been often observed in some nonorgan-specific autoimmune diseases, such as systemic lupus erithematosus, rheumatoid artritis, systemic sclerosis, and Sjogren syndrome; moreover, it has been also described in some organ-specific autoimmune diseases, such as type 1 diabetes mellitus, Graves' diseases (GD), Hashimoto's thyroiditis (HT), Addison's disease (AD), lymphocytic hypophysitis (LYH), celiac disease (CD), and multiple sclerosis (MS) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . But there is still considerable controversy concerning the true immunomodulatory role of PRL, and the subject deserves further investigation.
In this study, we attempted to establish whether there is a relationship between HPRL and primary thyroid disorders, focusing on patients with autoimmune features.
MATERIALS AND METHODS
This is a retrospective study in endocrinology outpatient clinics of a tertiary reference center in the period from January 2005 to April 2013. All HPRL cases with a records of thyroid ultrasonography (USG) and at least one measurement of basal serum thyroid stimulating hormone (TSH), circulating free thyroxine (fT4), free triiodothyronine (fT3), antithyroglobulin (anti-Tg), and/or antithyroperoxidase (anti-TPO) antibodies, were selected for inclusion. Women who were breastfeeding, using oral contraceptives, or pregnant were not enrolled. All patients participated in the study after signing an informed consent form. The local Ethics Committee of our hospital approved the study.
Venous blood samples were drawn between 8 am and 9 am from all the patients while fasting. Serum PRL, fT4, fT3, TSH, anti-Tg, and anti-TPO levels were measured by immunoassay using commercial kits. The normal ranges were: fT3: 1.8-4.6 pg/mL, fT4: 0.9-1.7 ng/ dL, TSH: 0.27-4.2 uIU/mL; anti-Tg: 0-115 IU/mL and anti-TPO: 0-34 IU/mL. Anti-Tg and anti-TPO titers that showed three standard deviations above the mean were considered positive. HPRL was defined as serum prolactin level > 29.9 ng/mL, according to the reference assay provided by the manufacturer. The thyroid USG was performed with a Logic 200 scanner using a 7.5 MHz linear array transducer and direct contact technique by an experienced endocrinologist. Goiter was diagnosed when the anteroposterior diameter of both lobes was ≥ 20 mm, or when any nodule was detected. The presence of a diffuse hypoechoic pattern with or without hyperechoic lines was considered suggestive of thyroiditis. A patient was defined as having primary thyroid disorders by one or more of the following diagnostic criteria: (i) goiter, (ii) positive anti-thyroid antibodies, and/or (iii) primary thyroid function abnormalities.
A control group, matched by age and gender with HPRL patients, was used for this study. All subjects denied having known thyroid diseases or relatives with any kind of thyroid disorders. In the control group, TFTs and autoantibody panel were obtained and thyroid USG was performed.
Results were expressed as medians (range). Data between groups were analyzed by the Mann-Whitney U test, as appropriate for normality, and comparisons between categorical data was performed by Chi-square test with Yates' correction. Statistical analysis was performed by SPSS software (Statistical Package for the Social Sciences, version 18.0, SSPS Inc., Chicago, IL, USA). A P value of less than 0.05 was considered statistically significant.
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RESULTS
Group 1 included 100 patients (mean age: 37.1 ± 10.9 years, range 17-63) and group 2 included 100 control subjects (mean age: 39.9 ± 10.5 years, range 21-68). There were 17 males (17%) and 83 females (83%) in each group. There were no significant differences between the two groups with respect to sex and age (P > 0.05). The median PRL in patients was 93 ng/mL (range: 37-470). The median duration of HPRL was 3 years (range: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . HPRL was caused by prolactinoma in 93 (93%), antipsychotic drugs in 4 (4%), and stalk compression by nonfunctional pituitary adenoma in 3 (3%) patients. HPRL was successfully controlled by cabergoline in 85 (85%), bromocriptine in 4, and by the combination of the two agents in 11 patients.
The results of the evaluation of TFTs and thyroid autoantibody panel are shown in table 1. The fT4 was significantly lower in group 1 (P = 0.009), but the median fT4 levels was still within normal range in both groups ( Table 1) . The proportion of patients with subclinical hypothyroidism was significantly higher in group 1 compared with group 2 (25% vs. 3%, P < 0.001). There were no significant differences between the two groups with respect to autoantibody positivity and the proportion of patients with ultrasonographic evidence of goiter or thyroiditis (P > 0.05). On the other hand, TFTs abnormalities were more frequent in HPRL patients (60%, out of 25 patients, 14 subclinical hypothyroidism and one hyperthyroidism) than in controls (9.1%, out of 22 patients, 2 subclinical hyperthyroidism) when individuals with autoantibody positivity were considered (P < 0.001). Characteristics of 25 HPRL patients who had evidence of thyroid autoimmunity during follow-up are shown in table 2. The median serum PRL was 98 (37-470) ng/mL in patients with positive thyroid autoantibodies and 92 (40-470) ng/mL in patients who tested negative for thyroid autoantibodies (P = 0.975). Fortysix patients (46%) and 50 (50%) control subjects had one or more of the features of thyroid disorder, which were goiter, positive thyroid autoantibody, and thyroid function abnormality (P = 0.888). The median serum PRL was 98.1 (37-470) ng/mL in patients with any feature of primary thyroid disorder and 91 (40-470) ng/ mL in the remaining patients in group 1 (P = 0.691).
DISCUSSION
Autoimmune diseases result from failure of selftolerance. A balance between positive and negative regulatory factors, both of genetic and environmental in origin, may control the susceptibility to these diseases and their progression. A shift in the balance between T helper (Th)1 and Th2 cytokine responses has been suggested to play a role in the development of autoimmune diseases. There is evidence that PRL influences the cellular arm of immune defense (20) . PRL can interfere with glucocorticoid-induced maturation of Th2 lymphocytes in addition to inducing the synthesis of IFN& and IL-2 by human leukocytes (21) . PRL increases the molecules involved in dendritic cell-T cell interaction and acts on the T cell receptor-stimulated Th1 maturation of T cells. PRL displays a predominant Th1 differentiation effect on purified T lymphocytes (20) . Data provided so far point at promotion of the development of Th1 cytokine profile by PRL, although HPRL is not always associated with a Th1 profile in vivo. Autoimmune diseases are often characterized by altered PRL levels, associated wtih both Th1 of Th2 dominance, which suggest an immunomodulatory role of PRL (21). There are several clinical studies that demonstrate a relationship between HPRL and autoimmune thyroid disease (15, (22) (23) (24) . Giusti and cols. showed that the prevalence of thyroid ultrasonographic alterations including goiter and chronic thyroiditis (30.8% vs. 15.5%) and the prevalence of autoantibodies (29.6% vs. 14.3%) were significantly higher in HPRL than in controls (15) . Another report by Ferrari and cols. reported comparable results: in a group of 82 women with HPRL, 20% had anti-Tg and 12% had anti-microsomal antibodies (22) . Most patients were euthyroid in this study. In a series by Kramer and cols., positivity for any of the thyroid autoantibodies was 57.1% in untreated HPRL, 10% in HPRL on treatment, and 3.6% in the control group (23) . Last, Poyraz and cols. analyzed a group of schizophrenic patients and observed that the prevalence of HPRL was significantly higher in patients positive for thyroid autoantibodies (81%), when compared with patients negative for them (49%). Serum levels of PRL were also significantly higher in patients with positivity for thyroid autoantibodies in that series (24) . Despite the studies mentioned above, literature is still scarce with respect to primary thyroid disorders in patients with HPRL.
Anti-TG and anti-TPO are indicators of thyroid inflammation and detection of these autoantibodies is a very specific means of diagnosing autoimmune thyroid disease (25, 26) . In this series of patients, among the individuals with autoantibody positivity TFTs abnormalities were more frequent in HPRL patients than in controls (60% vs. 9.1%, P < 0.001). This finding made us think that HPRL might be associated with a more severe thyroid inflammation leading to organ dysfunction in patients with the features of autoimmune disease. In this regard, our results agree with those of the above-mentioned studies which suggest a coexistence of autoimmune thyroid disease and HPRL (15, (22) (23) (24) . On the other hand there was no difference between the patients and controls with respect to antithyroid autoantibody positivity (25 vs. 22%, P = 0.739). And the median serum PRL was not significantly higher in patients with positive thyroid autoantibodies compared with the patients who were negative. There may be several explanations for this conflict. First, a study investigating such an association should be a prospective randomized controlled trial with a large number of participants. Second, the relevant studies should take into consideration several possible confounding factors, such as iodine status, personal or family history of autoimmune disease, certain medications (e.g., immunosuppressants, amiodarone). The above-mentioned studies and ours do not meet these two requirements (15, (22) (23) (24) . Third, a simple relationship between HPRL and autoimmune diseases may not be observed on every occasion because of the complexity of the immune system. Although PRL abnormalities have been reported in immune system disorders, it has not been possible to influence the course of these diseases by manupilating PRL release in any randomized controlled trial.
The prevalence of thyroid ultrasonographic alterations including goiter and thyroiditis was not more prevalent in our patients with HPRL. Endocrinologists are more inclined to screen patients with HPRL under their care for thyroid dysfunction and thyroid nodules than general practitioners. For this reason we think that such a relationship can only be demonstrated by randomized, prospective, double-blind, placebo-controlled trials.
In conclusion, our study results did show a remarkably high prevalence of thyroid dysfunction in patients with HPRL and thyroid autoimmunity, but thyroid autoimmunity and goiter were not more frequent. Autoimmunity is a complex process and the results of similar series in the literature should be cautiously interpreted. Future prospective studies on larger populations are needed to provide irrefutable evidence to support a direct causative link between HPRL and autoimmune thyroid disease.
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